Diaceutics | Personalized Medicine Consulting / Consultant

Diaceutics Exclusive Leadership eBrief

Diaceutics returned to several of the companies analyzed in their 2011 Pharma Readiness for PM report and asked executive leaders about the current status of their company’s PM strategy.

Download Now

CASE STUDY:
HERCEPTIN
Genentech

How multiple areas of patient “leakage” in the diagnostic program led to the loss of patients and several billion dollars in prescriptions.

View the Case Study »
CASE STUDY:
Epzicom
GlaxoSmithKline

The positive impact of taking a proactive approach to a targeted safety strategy.

View the Case Study »
CASE STUDY:
Selzentry
Pfizer

A loose partnering strategy and exclusive diagnostic relationship causes a negative impact on therapy sales.

View the Case Study »
CASE STUDY:
Tysabri
Elan/Biogen Idec

Post approval identification of the need for a diagnostic, handled correctly, can actually improve a drugs commercial success.

View the Case Study »
CASE STUDY:
Xalkori
Pfizer

Smart choices in test technology leads to rapid adoption but test cost presents a major issue for payers and patients.

View the Case Study »

PM Insights

Join us for a complimentary webinar on June 6th

PM 2.0 - An integrated approach to personalized medicine... Click Here

Expert Insights

Click Here

Mystery Solved! What is the...

A virtual expert panel of 4... + More

Unlocking the financial promise of personalized medicine

Helping the pharmaceutical and diagnostic industries understand how to leverage companion and other tests to achieve therapy goals.

Introducing Diaceutics DxExcellence Primer

A web-based educational and training resource to accelerate personalized medicine success.

Is your team ready for personalized medicine?

Find out -- take our online PM Readiness Test.

New Xalkori/Zelboraf Research Report

A unique opportunity to explore the launch, reimbursement and adoption of two groundbreaking PM approvals.

PM Insights